Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Maurizio Zangari to Risk Factors

This is a "connection" page, showing publications Maurizio Zangari has written about Risk Factors.

 
Connection Strength
  
 
 
0.426
  
  1. Zangari M, Berno T, Zhan F, Tricot G, Fink L. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost. 2012 Nov; 38(8):768-79.
    View in: PubMed
    Score: 0.063
  2. Zangari M, Zhan F, Tricot G. Bone and paraproteinemias. Curr Opin Support Palliat Care. 2010 Sep; 4(3):195-9.
    View in: PubMed
    Score: 0.054
  3. Zangari M. Anticoagulation regimens for thalidomide and lenalidomide. Clin Adv Hematol Oncol. 2006 Sep; 4(9):658-9.
    View in: PubMed
    Score: 0.041
  4. Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, Shah MR, Bag A, D'Souza A, Schinke C, Chakraborty R, Shah N, Mohan M. Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. Br J Haematol. 2024 Nov; 205(5):1830-1834.
    View in: PubMed
    Score: 0.036
  5. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003 Jun; 4(1):32-5.
    View in: PubMed
    Score: 0.033
  6. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002 Aug 15; 100(4):1168-71.
    View in: PubMed
    Score: 0.031
  7. Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Davies FE, Walker BA, van Rhee F, Morgan GJ. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. Br J Haematol. 2021 10; 195(2):283-286.
    View in: PubMed
    Score: 0.029
  8. Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, Schinke C, Thanendrarajan S, Davies FE, Hoering A, Morgan GJ. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020 Jan 28; 4(2):422-431.
    View in: PubMed
    Score: 0.026
  9. Mohan M, Susanibar-Adaniya S, Buros A, Crescencio JCR, Burgess MJ, Lusardi K, Davies F, Morgan G, Vanrhee F, Zangari M, Schinke C, Thanendrarajan S, Kothari A. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transpl Infect Dis. 2019 Apr; 21(2):e13052.
    View in: PubMed
    Score: 0.024
  10. Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2019 02; 184(4):578-593.
    View in: PubMed
    Score: 0.024
  11. Kim JH, Goulston C, Sanders S, Lampas M, Zangari M, Tricot G, Hanson KE. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1753-8.
    View in: PubMed
    Score: 0.015
  12. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul; 150(1):28-38.
    View in: PubMed
    Score: 0.013
  13. Shaughnessy JD, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007 Jun; 137(6):530-6.
    View in: PubMed
    Score: 0.011
  14. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84.
    View in: PubMed
    Score: 0.010
  15. Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol. 2005 Aug 01; 23(22):5217-23.
    View in: PubMed
    Score: 0.009
  16. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003 Jan; 31(1):73-80.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.